Abstract
Testosterone has been used for substitution therapy in testicular and hypothalamopituitary diseases for almost six decades, with injectable testosterone esters and implanted testosterone pellets being the mainstay of treatment. Growing interest in the possible use of testosterone in nonclassical situations such as male contraception, aging (late-onset hypogonadism), muscle-wasting conditions like HIV, erectile dysfunction, and female hypoactive sexual disorder has stimulated research, leading to the development of several new modes of administration of testosterone. Transdermal patches, gels, mucoadhesive sustained-release buccal tablets and long-acting testosterone esters are designed to provide testosterone levels that approximate normal physiologic levels, to improve patient acceptability, and to further increase the number of treatment options available. In this Review, we briefly describe the chemistry, mechanism of action, and metabolism of testosterone. We then discuss the pharmacokinetics, advantages, and disadvantages of various formulations and summarize the various preparations currently available.
Key Points
-
Testosterone is an effective and safe form of physiologic hormone replacement for lifelong treatment of male hypogonadism
-
The choice of testosterone preparation is often a compromise between multiple considerations including perceived efficacy, convenience, adverse effects, cost, availability, and patient acceptance and preference
-
Testosterone pellets, surgically implanted, provide stable physiologic levels for 4–6 months, although they are not universally available
-
Shorter-acting parenteral testosterone esters are associated with supraphysiologic and subphysiologic fluctuations in circulating testosterone levels
-
Long-acting testosterone undecanoate injections and testosterone gel are more likely to provide stable physiologic levels than other preparations
-
Selective androgen-receptor modulators are promising novel nonsteroidal synthetic compounds, currently under clinical testing, that mimic the biological effects of testosterone with tissue-selective actions
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Amory JK et al. (2005) Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. J Clin Endocrinol Metab 90: 2610–2617
Page ST et al. (2006) Oral nanomilled testosterone (T) plus dutasteride normalizes serum T in medically castrated men: a pharmacokinetic study. Presented at The Endocrine Society's 88th Annual Meeting (ENDO 2006) June 24–27, Boston, MA, USA
Zitzmann M et al. (2001) The CAG repeat polymorphism in the androgen receptor gene affects bone density and bone metabolism in healthy males. Clin Endocrinol (Oxf) 55: 649–657
Zitzmann M et al. (2001) The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity. J Clin Endocrinol Metab 86: 4867–4873
Gorczynska E et al. (1995) Androgens rapidly increase the cytosolic calcium concentration in Sertoli cells. Endocrinology 136: 2052–2059
Castoria G et al. (2003) Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. J Cell Biol 161: 547–556
Papakonstanti EA et al. (2003) A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors. Mol Endocrinol 17: 870–881
Jockenhovel F et al. (1996) Pharmacokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men. Clin Endocrinol (Oxf) 45: 61–71
Kelleher S et al. (2004) Testosterone release rate and duration of action of testosterone pellet implants. Clin Endocrinol (Oxf) 60: 420–428
Handelsman DJ et al. (1990) Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 71: 216–222
Kelleher S et al. (1999) Extrusion of testosterone pellets: a randomized controlled clinical study. Clin Endocrinol (Oxf) 51: 469–471
Handelsman DJ et al. (1997) An analysis of testosterone implants for androgen replacement therapy. Clin Endocrinol (Oxf) 47: 311–316
Kelleher S et al. (2001) Influence of implantation site and track geometry on the extrusion rate and pharmacology of testosterone implants. Clin Endocrinol (Oxf) 55: 531–536
Anderson RA et al. (1996) Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. II. Pharmacokinetics and pharmacodynamics of once weekly administration of testosterone enanthate. J Clin Endocrinol Metab 81: 896–901
Wu FC et al. (1996) Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Fertil Steril 65: 626–636
Snyder PJ et al. (1980) Treatment of male hypogonadism with testosterone enanthate. J Clin Endocrinol Metab 51: 1335–1339
Nieschlag E et al. (1976) Bioavailability and LH-suppressing effect of different testosterone preparations in normal and hypogonadal men. Horm Res 7: 138–145
Behre HM et al. (2004) Pharmacology of testosterone preparations. In Testosterone: Action, Deficiency, Substitution, 405–444 (Eds Nieschlag E and Behre HM) UK: Cambridge University Press
Bhasin S et al. (2006) Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 91: 1995–2010
Schulte-Beerbuhl M et al. (1980) Comparison of testosterone, dihydrotestosterone, luteinizing hormone, and follicle-stimulating hormone in serum after injection of testosterone enanthate of testosterone cypionate. Fertil Steril 33: 201–203
Nankin HR (1987) Hormone kinetics after intramuscular testosterone cypionate. Fertil Steril 47: 1004–1009
Schurmeyer T et al. (1984) Comparative pharmacokinetics of testosterone enanthate and testosterone cyclohexanecarboxylate as assessed by serum and salivary testosterone levels in normal men. Int J Androl 7: 181–187
Fukutani K et al. (1974) Effects of depot testosterone therapy on serum levels of luteinizing hormone and follicle-stimulating hormone in patients with Klinefelter's syndrome and hypogonadotropic eunuchoidism. J Clin Endocrinol Metab 39: 856–864
Wang C et al. (1996) Testosterone replacement therapy improves mood in hypogonadal men—a clinical research center study. J Clin Endocrinol Metab 81: 3578–3583
Davidson JM et al. (1979) Effects of androgen on sexual behavior in hypogonadal men. J Clin Endocrinol Metab 48: 955–958
Katznelson L et al. (1996) Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 81: 4358–4365
Matsumoto AM et al. (1985) Testosterone replacement in hypogonadal men: effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (Oxf) 22: 713–721
Liu PY et al. (2003) The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab 88: 3605–3613
Dobs AS et al. (1999) Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 84: 3469–3478
Sih R et al. (1997) Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 82: 1661–1667
Mackey MA et al. (1995) Tolerability of intramuscular injections of testosterone ester in oil vehicle. Hum Reprod 10: 862–865
Behre HM et al. (1999) Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 140: 414–419
von Eckardstein S et al. (2002) Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 23: 419–425
Schubert M et al. (2004) Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89: 5429–5434
Behre HM et al. (1992) Testosterone buciclate (20 Aet-1) in hypogonadal men: pharmacokinetics and pharmacodynamics of the new long-acting androgen ester. J Clin Endocrinol Metab 75: 1204–1210
Behre HM et al. (1995) Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab 80: 2394–403
Bhasin S et al. (1992) A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men. J Clin Endocrinol Metab 74: 75–83
Amory JK et al. (2002) Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men. J Androl 23: 84–91
Bagchus WM et al. (2001) Bioequivalence of andriol and andriol testocaps. Aging Male 4: 259
Cantrill JA et al. (1984) Which testosterone replacement therapy? Clin Endocrinol (Oxf) 21: 97–107
Gooren LJ (1994) A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 15: 212–215
Holmang S et al. (1993) Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate 23: 99–106
Conway AJ et al. (1988) Randomized clinical trial of testosterone replacement therapy in hypogonadal men. Int J Androl 11: 247–264
Schubert M et al. (2003) Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res 60: 21–28
Haren M et al. (2005) Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status. Age Ageing 34: 125–130
Park NC et al. (2003) Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency. Aging Male 6: 86–93
Skakkebaek NE et al. (1981) Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf) 14: 49–61
Wittert GA et al. (2003) Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 58: 618–625
Foss GL et al. (1959) Oral methyltestosterone and jaundice. Br Med J 34: 259–263
Ishak KG et al. (1987) Hepatotoxic effects of the anabolic/androgenic steroids. Semin Liver Dis 7: 230–236
Nieschlag E et al. (2005) Investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 8: 56–58
Petry R et al. (1968) Androgen treatment without inhibiting effect on hypophysis and male gonads. Biochemical and morphological studies after treatment with Mesterolone. Acta Endocrinol (Copenh) 59: 497–507
Aakvaag A et al. (1974) The effect of mesterolone administration to normal men on the pituitary-testicular function. Acta Endocrinol (Copenh) 77: 380–386
Bals-Pratsch M et al. (1988) Substitution therapy of hypogonadal men with transdermal testosterone over one year. Acta Endocrinol (Copenh) 118: 7–13
Bals-Pratsch M et al. (1986) Transdermal testosterone substitution therapy for male hypogonadism. Lancet 2: 943–946
Behre HM et al. (1999) Long-term substitution therapy of hypogonadal men with transscrotal testosterone over 7–10 years. Clin Endocrinol (Oxf) 50: 629–635
Findlay JC et al. (1987) Transdermal delivery of testosterone. J Clin Endocrinol Metab 64: 266–268
Behre HM et al. (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82: 2386–2390
Korenman SG et al. (1987) Androgen therapy of hypogonadal men with transscrotal testosterone systems. Am J Med 83: 471–478
Flamigni C et al. (1971) Androgen metabolism in human skin. J Clin Endocrinol Metab 32: 737–743
Arver S et al. (1997) Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf) 47: 727–737
Arver S et al. (1996) Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 155: 1604–1608
Meikle AW et al. (1997) Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 49: 191–196
Swerdloff RS et al. (2000) Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 85: 4500–4510
Wang C et al. (2000) Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study. J Clin Endocrinol Metab 85: 964–969
Rolf C et al. (2002) Pharmacokinetics of a new transdermal testosterone gel in gonadotrophin-suppressed normal men. Eur J Endocrinol 146: 673–679
Wang C et al. (2004) Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89: 2085–2098
Swerdloff RS et al. (2003) Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male 6: 207–211
Wang C et al. (2000) Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 85: 2839–2853
Rolf C et al. (2002) Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation. Clin Endocrinol (Oxf) 56: 637–641
Korbonits M et al. (2004) A comparison of a novel testosterone bioadhesive buccal system, striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab 89: 2039–2043
Wang C et al. (2004) New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 89: 3821–3829
Dobs AS et al. (2004) Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient men. Curr Med Res Opin 20: 729–738
von Eckardstein S et al. (2003) A clinical trial of 7 alpha-methyl-19-nortestosterone implants for possible use as a long-acting contraceptive for men. J Clin Endocrinol Metab 88: 5232–5239
Anderson RA et al. (1999) 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J Clin Endocrinol Metab 84: 3556–3562
Anderson RA et al. (2003) Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men. J Clin Endocrinol Metab 88: 2784–2793
Gao W et al. (2005) Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology 146: 4887–4897
Chen J et al. (2005) A selective androgen receptor modulator for hormonal male contraception. J Pharmacol Exp Ther 312: 546–553
Rosen J et al. (2002) Novel, non-steroidal, selective androgen receptor modulators (SARMs) with anabolic activity in bone and muscle and improved safety profile. J Musculoskelet Neuronal Interact 2: 222–224
Wu FC (1992) Testicular steroidogenesis and androgen use and abuse. Baillieres Clin Endocrinol Metab 6: 373–403
Acknowledgements
We are grateful to Mr Harry Heyes from the medical illustration department at Manchester Royal Infirmary for his assistance with the figures.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
Dr U Srinivas-Shankar has received reimbursement for attending a conference from Schering AG, Berlin, Germany.
Professor FCW Wu has served as a paid consultant and received lecture fees and travel grants from Schering AG, Berlin, Germany; Organon BV Oss, The Netherlands; Pierre Fabre Medicaments, Castre, France; Ardana, Edinburgh, UK; and Proctor and Gamble, USA.
Rights and permissions
About this article
Cite this article
Srinivas-Shankar, U., Wu, F. Drug Insight: testosterone preparations. Nat Rev Urol 3, 653–665 (2006). https://doi.org/10.1038/ncpuro0650
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpuro0650
This article is cited by
-
Intramuscularly injected long-acting testosterone-cholesterol prodrug suspension with three different particle sizes: extended in vitro release and enhanced in vivo safety
Drug Delivery and Translational Research (2023)
-
Effects of hormonal treatment on dermatological outcome in transgender people: a multicentric prospective study (ENIGI)
Journal of Endocrinological Investigation (2022)
-
Can conditions of skeletal muscle loss be improved by combining exercise with anabolic–androgenic steroids? A systematic review and meta-analysis of testosterone-based interventions
Reviews in Endocrine and Metabolic Disorders (2021)
-
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer
Investigational New Drugs (2018)
-
Androgen receptor: structure, role in prostate cancer and drug discovery
Acta Pharmacologica Sinica (2015)